EICHORCondition: Breast Cancer · Solid Tumor · Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
This study is an open-label, multicenter, dose-escalation and expansion, non-randomized Phase I clinical study evaluating the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of SI-B036 bispecific antibody injection in patients with locally advanced or metastatic breast cancer and other solid tumors.
This description comes directly from the study's public registry record.
Sa Xiao, PHD · +8615013238943 · xiaosa@baili-pharm.com
Always discuss trial participation with your own doctor first.
| Cancer Hospital Chinese Academy of Medical Sciences | Beijing, Beijing Municipality, China | — |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07753226